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p62Dok, the rasGAP-binding protein, is a common tar-
get of protein-tyrosine kinases. It is one of the major
tyrosine-phosphorylated molecules in v-Src-trans-
formed cells. Dok consists of an amino-terminal Pleck-
strin homology domain, a putative phosphotyrosine
binding domain, and a carboxyl-terminal tail containing
multiple tyrosine phosphorylation sites. The impor-
tance and function of these sequences in Dok signaling
remain largely unknown. We have demonstrated here
that the expression of Dok can inhibit cellular transfor-
mation by the Src tyrosine kinase. Both the phosphoty-
rosine binding domain and the carboxyl-terminal tail of
Dok (in particular residues 336–363) are necessary for
such activity. Using a combinatorial peptide library ap-
proach, we have shown that the Dok phosphotyrosine
binding domain binds phosphopeptides with the con-
sensus motif of Y/MXXNXL-phosphotyrosine. Further-
more, Dok can homodimerize through its phosphoty-
rosine binding domain and Tyr146 at the amino-terminal
region. Mutations of this domain or Tyr146 that block
homodimerization significantly reduce the ability of
Dok to inhibit Src transformation. Our results suggest
that Dok oligomerization through its multiple domains
plays a critical role in Dok signaling in response to ty-
rosine kinase activation.
p62Dok, the rasGAP-binding protein, is a common target of
protein-tyrosine kinases (PTKs).1 It is one of the major ty-
rosine-phosphorylated molecules in v-Src-, v-Abl-, and v-Fps-
transformed cells and is also rapidly tyrosine-phosphorylated
in response to receptor tyrosine kinase activation in various
cell systems (1–5). These findings have underlined the impor-
tance of p62Dok in cellular signaling.
Recent molecular cloning of Dok has shed more light on the
mechanism by which this protein may interact with PTK sig-
naling pathways (4, 6). Dok consists of an amino-terminal
Pleckstrin homology (PH) domain, a putative phosphotyrosine
binding (PTB) domain, and a carboxyl-terminal tail harboring
at least seven potential tyrosine phosphorylation sites (4, 6).
The PH domain is likely to be necessary for targeting Dok to
the membrane, because PH domains preferentially bind phos-
pholipids (7). The putative PTB domain is most homologous to
the IRS-1 and FRS2/SNT-1 PTB domains, which recognize
phosphotyrosine (pY)-containing sequences (8–11). In the case
of SNT-1, its PTB domain can also bind distinct unphosphoryl-
ated sequences (11). It remains to be determined whether the
Dok PTB domain can bind phosphopeptides and, if it does,
whether it recognizes sequences distinct from those recognized
by the IRS-1 and SNT-1 PTB domains. The multiple tyrosine
residues in the Dok carboxyl-terminal tail are candidate sites
for tyrosine kinases. When phosphorylated, they become poten-
tial docking sites for Src homology 2-containing proteins such
as p120 rasGAP and Nck (5, 12). Consistent with this notion,
both rasGAP and Nck have been shown to bind tyrosine-phos-
phorylated Dok (4, 13). Therefore, the carboxyl-terminal tail of
Dok likely functions as a molecular platform for signal complex
assembly induced by activated PTKs. However, the functional
significance of the Dok PTB domain and the carboxyl-terminal
tail has yet to be addressed.
Additional Dok homologues such as Dok-L (or Dok-3) and
Dok-R (or Dok-2 and FRIP) have been identified recently (14–
18), indicating that Dok and its homologues may constitute a
growing family of proteins involved in a range of signaling
pathways downstream of PTKs. However, the physiological
roles of Dok and its homologues remain to be elucidated. De-
spite their structural similarities to the IRS-1 family mole-
cules, Dok family proteins have different PTB domains and
carboxyl-terminal tails that potentially mediate different sig-
nal responses by recruiting distinct sets of Src homology 2-con-
taining signaling molecules. The mechanism by which Dok is
phosphorylated and primed to form specific signaling com-
plexes thus becomes a key issue in understanding Dok signal-
ing. We have demonstrated here that the Dok PTB domain is a
functional phosphotyrosine binding module that facilitates ty-
rosine phosphorylation and rasGAP binding of Dok. We have
also found that Dok can inhibit Src-induced cellular transfor-
mation. This inhibitory effect depends on both the PTB domain
and the carboxyl-terminal tail of Dok. Furthermore, we have
shown that Dok can oligomerize via its PTB domain and Tyr146.
This oligomerization appears critical for the inhibition of v-Src-
induced transformation. These results suggest that the multi-
ple domains of Dok are required for Dok signaling.
EXPERIMENTAL PROCEDURES
Cell Lines and Antibodies—NIH3T3 cells were maintained in Dul-
becco’s modified Eagle’s media containing 10% calf serum (Hyclone).
The anti-hemagglutinin (HA) monoclonal antibody was purchased from
Berkeley Antibody Company. The anti-His-tag, anti-rasGAP, and anti-
phosphotyrosine monoclonal antibodies (4G10 and PY20) were pur-
chased from Santa Cruz Biotechnology. Anti-Ras monoclonal antibody
was from Upstate Biotechnology.
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DNA Constructs—The coding region of the murine Dok cDNA (4)
tagged with the HA epitope was cloned into the HpaI site of the murine
stem cell retroviral vector MSCVpuro (19). The HA epitope was joined
to the 59 end of Dok cDNA by polymerase chain reaction (PCR) using the
pfu polymerase (4). The carboxyl-terminal truncated forms of Dok were
similarly cloned. The Dok 277, 313, 336, and 363 constructs encode
amino acids 1–277, 313, 336, and 363, respectively. The PTB domain
mutant Dok-AA (Arg207 and Arg208 to Ala) and the Y146F mutants
(DokN-Y146F, Dok313-Y146F, and Dok363-Y146F) were generated by
site-directed mutagenesis using PCR with the pfu polymerase. All con-
structs were confirmed by DNA sequencing. Sequences encoding wild-
type (chicken c-Src) or activated (Src527F) Src were cloned into the
MSCV-neo vector as described previously (20).
Generation of Cell Lines Expressing Src and Dok Variants—The
MSCV-based constructs encoding Src and HA-Dok and their variants
were transfected into the retrovirus packaging cell line BOSC23 (21).
Retroviruses were harvested 2 days after transfection and used to infect
dividing NIH3T3 cells. Two days after infection, Dok- or Src-expressing
cells were selected in puromycin- or G418-containing media. Cells that
coexpressed Dok and Src were generated by infecting Dok-expressing
cells again with Src viruses followed by selection in G418-containing
media.
Transformation Assay—The ability of Src to induce cellular trans-
formation was scored by the focus formation assay in NIH3T3 cells.
Parental and Dok variant-expressing cells were infected by low titer
(1 3 104/ml) MSCV-c-Src or MSCV-Src527F viruses. These cells were
maintained in Dulbecco’s modified Eagle’s media containing 10% calf
serum for 7–10 days for focus formation. The number of foci were then
quantitated to determine transformation activities. Three replicate
dishes were plated for each sample, and each experiment was repeated
three times.
GST Fusion Proteins and Phosphopeptide Library—To generate the
glutathione S-transferase (GST) fusion protein construct containing
only the amino-terminal PH and PTB domains of Dok (GST-DokN), the
DNA fragment encompassing residues 1–277 of murine Dok was PCR-
amplified and cloned into the SmaI site of the pGEX4T-1 vector (Am-
ersham Pharmacia Biotech). Similarly, to generate the GST-PTB and
GST-PTB-AA constructs, the DNA fragment encoding residues 125–264
was PCR-amplified using wild-type Dok or Dok-AA as a template.
These fragments were subsequently cloned into the BamHI site of
pGEX4T-1. These constructs were used to transform Escherichia coli to
produce GST fusion proteins that were purified using glutathione-
agarose beads.
To study the binding specificity of the Dok PTB domain, 100–200 mg
of fusion proteins that were immobilized on glutathione-agarose beads
were incubated with 1 mg of peptide library. The peptide library had a
sequence of MAXXXNXXpYXAKKK, where X indicates any amino acid
except Cys and Trp. This particular library was designed to examine
PTB domain specificities, because PTB domains prefer turn-forming
sequences near pY and hydrophobic residues at 5–8 positions amino-
terminal to pY (22). The mixture of peptides bound to the fusion pro-
teins was eluted with acid after washing. This peptide mixture was then
sequenced on an ABI477 machine. The specificity of binding was then
determined by comparing the sequence of bound mixture with that of
the mock experiment using GST alone (12).
His-tagged Fusion Proteins and Src Phosphorylation—To generate
poly-His-tagged Dok (His-DokN) fusion proteins, sequences encoding
residues 1–264 of Dok were PCR-amplified and cloned into the BamHI
site of the pRSET vector (Invitrogen). His-DokN-Y146F was con-
structed in the same manner, except that Tyr146 was mutated to Phe.
His-tagged proteins were purified from BL21 cells using nitrilotriacetic
acid-agarose (Qiagen) and eluted with immidazole. To phosphorylate
these fusion proteins, they were incubated with 2 mg of purified recom-
binant c-Src (a generous gift from Dr. Wenqing Xu, University of Wash-
ington) in the presence of 1 mM ATP and 20 mM MgCl2 for 1 h at 30 °C.
Immunoprecipitation and Western Blot Analysis—Cells were washed
once with PBS, lysed in the lysis buffer (20 mM Tris, pH 8.0, 150 mM
NaCl, 1 mM EDTA, 10% glycerol, 1% Nonidet P-40, 1 mM phenlymeth-
ylsulfonyl fluoride, 1 mM pepstatin A, 1 mM aprotinin, 1 mM leupeptin, 2
mM b-glyerolphosphate, 500 mM sodium vanadate, and 1 mM dithiothre-
itol), and centrifuged at 10,000 3 g at 4 °C. The supernatants were
subsequently collected for immunobloting and immunoprecipitation.
For immunobloting, 1⁄10 of the supernatants was mixed with SDS-
loading buffer, boiled, and analyzed by SDS-polyacrylamide gel electro-
phoresis. For immunoprecipitation, the supernatants were incubated
with antibodies at 4 °C for 90 min. Protein A/G-agarose beads were then
added, and the mixture was incubated at 4 °C for another 90 min. The
beads were subsequently washed four times with lysis buffer, resus-
pended in SDS-loading buffer, and boiled, and the eluents were ana-
lyzed by SDS-polyacrylamide gel electrophoresis. SDS-polyacrylamide
gel electrophoresis and Western blot analyses were performed as de-
scribed previously (4).
Ras Activation Assay—For analyzing the effect of Dok expression on
Ras GTP loading in Src-transformed cells, GST-Raf Ras binding do-
main-agarose beads (Ras Activation Assay kit, Upstate Biotechnology)
were used to precipitate GTP-bound Ras as described in the manufac-
turer’s manual. A monoclonal antibody against Ras was also supplied in
the kit and used to probe for endogenous Ras.
RESULTS
Dok Can Inhibit Src-induced Cellular Transformation—Al-
though tyrosine phosphorylation of Dok occurs concurrently
with PTK activation, the exact role of Dok in cell signaling
remains ambiguous. To address the question of whether Dok
facilitates or inhibits Src transformation, we examined the
effect of Dok expression on Src-induced transformation in
NIH3T3 cells. Dok and Src retroviruses (see “Experimental
Procedures”) were used to infect NIH3T3 cells. As shown in Fig.
1, A and B, expression of c-Src or activated Src (Src527F)
readily induced focus formation within 1 week. However, coex-
pression of Dok and Src strongly inhibited focus formation
induced by Src. Although Dok is commonly phosphorylated by
oncogenic tyrosine kinases, this result indicates that the phys-
iological effect of DOK is to inhibit cellular transformation by
the Src-tyrosine kinase.
The Dok PTB Domain and Carboxyl-terminal Region Are
Necessary for Its Inhibitory Effects—Because Dok consists of
multiple domains, we went on to map the functional domains in
Dok that are responsible for its inhibitory effects. Mutant Dok
molecules that were HA epitope-tagged were generated and
coexpressed with Src in NIH3T3 cells. We postulated that the
multiple potential tyrosine phosphorylation sites within the
Dok carboxyl terminus might contribute to Dok inhibition of
Src transformation. Consistent with this notion, deletion of the
carboxyl-terminal tail (Dok277) abolished the inhibitory activ-
ity of Dok (Fig. 1B). Using a panel of carboxyl-terminal deletion
constructs, we further defined the regions within the Dok car-
boxyl terminus necessary for transformation inhibition. Al-
though Dok363 still blocked Src transformation, Dok313 and
Dok336 no longer retained the inhibitory abilities (Fig. 1B).
These data indicate that the residues between 336 and 363
constitute a functional domain for the inhibitory action of Dok.
To determine the role of the amino-terminal portion, muta-
tions were made in the putative PTB domain of Dok. On the
basis of sequence homology with the IRS-1 PTB domain (4),
amino acids Arg207 and Arg222 of Dok are predicted to coordi-
nate phosphotyrosine binding. We therefore reasoned that mu-
tation of Arg207 might block phosphotyrosine binding and
thereby affect Dok function. Supporting our hypothesis, muta-
tion of Arg207 and Arg208 to Ala residues (Dok-AA) eliminated
the inhibitory function of Dok (Fig. 1B). These results strongly
suggest that the Dok amino-terminal PTB domain represents a
distinct regulatory domain of Dok that may associate with
tyrosine-phosphorylated proteins.
Tyrosine Phosphorylation of Dok Mutant Proteins—Because
tyrosine phosphorylation of Dok may be critical for its in vivo
activities, we examined tyrosine phosphorylation of various
HA-tagged Dok mutants in Src527F-transformed NIH3T3 fi-
broblasts. The different Dok proteins including the PTB do-
main mutant (Dok-AA) and all carboxyl-terminal deletion mu-
tants (Dok277, -313, -336, and -363) were expressed (Fig. 2, A
and B). Western blots of whole cell lysates indicated that they
were all tyrosine-phosphorylated (data not shown). Surpris-
ingly, Western blots of anti-HA immunoprecipitates that were
probed with anti-phosphotyrosine antibodies showed that even
Dok277 (which lacks the carboxyl-terminal region with its mul-
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FIG. 1. Expression of Dok can inhibit Src transformation. Parental and HA-tagged Dok-expressing NIH3T3 fibroblast cells were infected
with c-Src or Src527F retroviruses. The effect of various Dok mutants on Src transformation was studied using a focus formation assay in these
cells. A, culture morphology of cells expressing c-Src alone (left) or both c-Src and Dok (right). B, comparison of the focus-forming abilities of
parental NIH3T3 cells or those that coexpressed Dok variants with either c-Src (left) or Src527F (right). The numbers indicate the numbers of foci
formed per 104 Src viral particles. C, diagram of different Dok deletion mutants and mapping of domains that are required for Dok inhibitory
function. 1, inhibition; 2, no inhibition.
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tiple potential phosphorylation sites) was still tyrosine-phos-
phorylated (Fig. 2B), suggesting that a major tyrosine phospho-
rylation site is located in the amino-terminal domain of Dok.
Therefore, changes in the gross tyrosine phosphorylation levels
of various Dok mutants induced by the Src PTK may not
account for the differences in their inhibitory abilities. How-
ever, phosphorylation of specific tyrosine sites on Dok may be
necessary for inhibition of Src-mediated transfromation.
Dok PTB Domain Binds to Specific Phosphopeptide Sequenc-
es—We have shown here that the Dok PTB domain (residues
125–264) is functional and necessary for Dok to inhibit Src-
induced transformation, possibly through its interaction with
phosphotyrosine-containing proteins. However, whether the
Dok PTB domain does indeed bind specific phosphotyrosine-
containing sequences remains to be determined. To this end,
we used a combinatorial peptide library approach (see “Exper-
imental Procedures”).
Briefly, GST fusion proteins containing either the Dok ami-
no-terminal PH and PTB domains (GST-DokN) or the Dok PTB
domain alone (GST-PTB) were purified and captured on GSH
beads. The beads were then incubated with a soluble degener-
ate phosphopeptide library mixture to select for specific pep-
tides that would bind to the PTB domains. The peptide library
used had a sequence of MAXXXNXXpYXAKKK. The amino
acid at position 23 to the phosphotyrosine was fixed (Asn),
because PTB domains prefer turn-forming sequences (9, 22).
The phosphopeptide mixtures that bound specifically to the
Dok PTB domain were then isolated and sequenced by Edman
degradation. A comparison of these sequences to those obtained
using GST alone revealed that the Dok PTB domain recognizes
phosphopeptides with the unique motif of Y/MXXNXLpY (Fig.
3). At position pY-1, Leu was exclusively selected, indicating
the importance of this residue. At position pY-6, hydrophobic
amino acids Tyr, Met, and Phe were strongly selected. Similar
preferences for hydrophobic residues at positions pY-5 to pY-8
have been reported for other PTB domains as well (8, 22).
A region within the Dok PTB domain (amino acids 204–232)
is 41 and 52% identical to those of IRS-1 and SNT-1, respec-
tively. The latter two PTB domains bind phosphopeptides with
the consensus motif of NPXpY (8–11). Importantly, two critical
Arg residues (Arg207 and Arg222) that are known to mediate
phosphotyrosine recognition in the IRS-1 PTB domain are con-
served in the Dok PTB domain as well (Arg207 and Arg222). To
test whether Arg207 also mediates the interaction between the
Dok PTB domain and the phosphotyrosine moiety, we exam-
ined the Dok-AA mutant in which Arg207 was replaced with
Ala. As predicted, this mutation eliminated the ability of the
Dok PTB domain to bind phosphopeptides (data not shown).
Combined with the observation that Dok-AA could no longer
inhibit Src transformation, these data support the model that
Dok function depends on the PTB domain. Furthermore, de-
spite their similarities in the structural basis for phosphoty-
rosine recognition, the Dok PTB domain recognizes distinct
sequences (NXLpY) compared with the IRS-1 PTB domain
(NPXpY). Therefore, the Dok PTB domain may associate in
vivo with a set of tyrosine-phosphorylated proteins distinct
from that bound by IRS-1.
The Dok PTB Domain Mediates Phosphotyrosine-dependent,
Homotypic Interactions of Dok—We have shown that the PTB
domain recognizes specific tyrosine-phosphorylated sequences
and is required for the inhibitory activity of Dok. It is likely
that Dok may exert its inhibitory function by binding to specific
phosphoproteins through the PTB domain. To further investi-
gate the phosphoproteins that might associate with the PTB
domain and the mechanism by which the PTB domain might
FIG. 2. Expression and tyrosine phosphorylation of wild-type
and mutant Dok proteins. Lysates from cells that coexpressed vari-
ous HA-tagged Dok constructs with Src527F were immunoprecipitated
and Western blotted. A, expression of wild-type and mutant HA-tagged
Dok proteins in Src527F-transformed cells. Equal amounts of whole cell
lysates were resolved by SDS-polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes. The membranes were probed
with anti-HA antibodies. B, comparison of tyrosine phosphorylation of
HA-Dok, Dok-AA, and Dok277 proteins. Dok proteins were immunopre-
cipitated (IP) using anti-HA antibodies and probed with an anti-phos-
photyrosine antibody. p-Dok, phosphorylated Dok; p-Dok277, phospho-
rylated Dok277.
FIG. 3. The Dok PTB domain binds phosphopeptides with dis-
tinct sequences. The binding specificity of the Dok PTB domain was
examined using the phosphopeptide library MAXXXNXXpYXAKK. The
relative preference of amino acids at each degenerate position (pY as
position 0) was plotted. A value of $1 higher indicates a preferred
amino acid. Selections are shown at position -6 (A), position -5 (B),
position -4 (C), position -3 (D), position -2 (E), and position -1 (F).
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regulate Dok function, the GST-DokN fusion protein contain-
ing both PH and PTB domains was used to precipitate proteins
from Src-transformed cells. As shown in Fig. 4A, multiple ty-
rosine-phosphorylated bands were specifically copurified with
the Dok amino-terminal domain, including major proteins at
;60 kDa, which is similar to the molecular mass of Dok. We
therefore speculated that some of these proteins might be Dok
family members. To test this idea, GST-DokN fusion proteins
were incubated with cell lysates from Src-transformed cells
that also expressed various Dok mutants. Although GST alone
did not precipitate any Dok molecules, GST-DokN bound spe-
cifically to HA-tagged, wild-type Dok and various mutant Dok
proteins (Fig. 4B). The carboxyl-terminal tail of Dok is not
required for this interaction, because Dok277 appeared to bind
GST-DokN with the same efficiency as wild-type Dok. In addi-
tion, the GST-PTB domain alone was able to associate with
HA-tagged Dok277, indicating that the PTB domain may me-
diate homotypic interactions of Dok (Fig. 4C).
On the basis of our combinatorial peptide library mapping of
the consensus substrate motif (Y/MXXNXLpY) of the Dok PTB
domain, sequences surrounding residue Tyr146 (LEMLEN-
SLYS) on Dok constitute a perfect binding site for the Dok PTB
domain when this tyrosine is phosphorylated. Tyr146, located
between the Dok PH and PTB domains, is also a potential
tyrosine phosphorylation site for the Src family PTKs (24). We
hypothesized that Tyr146 might be necessary for the homotypic
interactions mediated by the Dok PTB domain. Consistent with
our hypothesis, the HA-tagged Dok mutant with its Tyr146
mutated to Phe (Dok313-Y146F) failed to copurify with the
GST-PTB domain, even though the GST-PTB domain fusion
proteins were able to pull down the Dok amino-terminal region
(Fig. 4C). These data strongly indicate a PTB domain-medi-
ated, direct interaction between Dok molecules.
PTB domains have been shown to mediate both phosphoty-
rosinedependent and -independent interactions. To confirm
that Dok-Dok interactions through the PTB domain were direct
and tyrosine phosphorylation-dependent, we generated the
His-tagged Dok amino-terminal domain (His-DokN) and His-
DokN with the Y146F mutation (His-DokN-Y146F) in E. coli.
These fusion proteins were in vitro-phosphorylated using re-
combinant c-Src and incubated with GST-Dok PTB. As shown
in Fig. 4D, only His-DokN was able to bind GST-Dok PTB,
although His-DokN and His-DokN-Y146F were equally phos-
phorylated by c-Src. In addition, the GST-PTB domain failed to
bind His-DokN in the absence of c-Src. These data demonstrate
that the Dok PTB domain mediates phosphotyrosine-depend-
ent homotypic interactions through residue Tyr146.
Tyr146 Is Important for Regulating Dok Activity—We showed
that Dok363 was the shortest mutant to still retain the inhib-
itory activity (Fig. 1). To determine the role of Tyr146 on Dok
function, Dok363 with the Tyr146 to Phe mutation (Dok363-
Y146F) was generated and compared with Dok363 for its effect
on Src-induced transformation in NIH3T3 cells. Notably, the
Y146F mutation significantly reduced the inhibitory activity of
Dok363 (Fig. 5). Therefore, mutations (in either the PTB do-
main or Tyr146) that prevent Dok oligomerization also abro-
gated its inhibitory activity. These results indicate that the
homotypic interaction through Tyr146 and the Dok PTB domain
is necessary for Dok function.
Dok Interacts with the Ras Pathway—Src is known to acti-
FIG. 4. The Dok PTB domain mediates oligomerization of Dok
proteins. A, the amino-terminal domain of Dok binds to phosphopro-
teins at ;60 kDa. The Dok amino-terminal domain fusion protein
(GST-DokN) or GST alone was incubated with lysates from Src527F-
expressing NIH3T3 cells. The associated proteins were then detected by
anti-phosphotyrosine antibodies and enhanced chemiluminescence. B,
the amino-terminal domain of Dok interacts with different Dok mutant
proteins. The GST-DokN fusion protein was incubated with lysates
from cells expressing various HA-tagged Dok mutants. As a negative
control, GST proteins were incubated with cell lysates from HA-Dok-
and Src527-coexpressing cells. Proteins that bound to GST or GST-
DokN were visualized using an anti-HA monoclonal antibody and en-
hanced chemiluminescence. p, cross-reactive bands. C, the Dok PTB
domain mediates homotypic interaction through Tyr146 of Dok. GST
fusion proteins of DokN (GST-DokN), Dok PTB (GST-PTB), and Dok
PTB mutant (GST-PTB AA) were incubated with lysates from cells
coexpressing Src527F and HA-tagged Dok277 or Dok313 with and
Tyr146 to Phe mutation (Dok313Y146F). Proteins that bound to GST
fusion proteins were visualized using an anti-HA monoclonal antibody
and enhanced chemiluminescence. D, the Dok PTB domain binds di-
rectly to the phosphorylated Tyr146 site. GST-PTB fusion proteins were
incubated with purified His-tagged DokN (right) or c-Src-phosphoryl-
ated, His-tagged DokN (His-DokN) and DokN-Y146F (His-DokNY146F;
left). Proteins that bound to the GST PTB domain were visualized using
anti-His-tag or anti-phosphotyrosine antibodies and enhanced
chemiluminescence.
FIG. 5. Tyr146 is important for the inhibitory activity of Dok.
Parental NIH3T3 fibroblast cells and those that expressed HA-tagged
Dok363 or Dok363-Y146F were infected with low-titer Src527F viruses.
Focus formation was then assayed to compare the effect of various Dok
mutants on Src transformation in these cells. Error bars indicate S.E.
from three independent experiments.
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vate the Ras pathway, and Dok is a rasGAP-binding protein.
We therefore reasoned that Dok might inhibit Src transforma-
tion by recruiting rasGAP, thereby regulating Ras activity in
the cell. V12Ras (activated Ras) is locked in the GTP-bound
state and therefore should be unaffected by rasGAP activity
(25). We first tested how Dok might affect V12Ras-mediated
transformation in NIH3T3 cells. Consistent with its rasGAP
binding ability, Dok expression did not affect focus formation
induced by activated V12-K-Ras (Fig. 6A), suggesting that Dok
likely acts upstream of Ras to block Ras activation.
We postulated that Dok might function by increasing the
local concentration of rasGAP. To test this hypothesis, anti-HA
immunoprecipitates from Src-transformed cells that also ex-
pressed full-length HA-tagged Dok, Dok363, Dok336, Dok277,
or Dok-AA were probed with anti-rasGAP antibodies (Fig. 6B).
Full-length Dok and Dok363 were able to associate with ras-
GAP; however, Dok336, Dok277, and the PTB domain mutant
Dok-AA were impaired in their abilities to bind rasGAP. The
inability to bind rasGAP may explain the failure of Dok336,
Dok277, and Dok-AA to inhibit Src transformation (Fig. 1B).
These results further imply that the PTB domain together with
the carboxyl-terminal region of Dok may function in clustering
and recruiting rasGAP to the site of action. We further specu-
lated that the recruitment of rasGap by Dok may lead to
inhibition of Ras GTP loading. Consistent with this idea, the
amount of Ras GTP (active Ras) was found to be significantly
reduced in Src-transformed cells coexpressing Dok compared
with Src-transformed cells (Fig. 6C).
DISCUSSION
We have shown that expression of Dok can block c-Src-
induced transformation in NIH3T3 fibroblasts, indicating that
Dok may negatively regulate signal pathways that are acti-
vated by PTKs. It is possible that Dok functions to recruit
negative regulators of PTK cascades. For example, Csk family
kinases are known to down-regulate c-Src activity by phospho-
rylating Tyr527 on c-Src (26, 27). Furthermore, Dok family
proteins have been reported to associate directly with Csk (18,
28, 29). These data suggest that Dok may attenuate Src sig-
naling by regulating Csk. However, this model was ruled out
because Dok also inhibits transformation by activated Src
(527F).
Alternatively, Dok may exert its inhibitory effects via the
GTPase-activating protein rasGAP. Several lines of evidence
support this hypothesis. First, Dok is a rasGAP-binding pro-
tein. Association of Dok with rasGAP can be readily detected
during activation of PTKs such as Src, Abl, and the Eph recep-
tor kinase (1–5). Among the seven potential tyrosine phospho-
rylation sites of Dok, five are predicted docking sites for the Src
homology 2 domains of rasGAP (4, 5). The presence of multiple
rasGAP binding sites on Dok suggests that Dok may provide
the molecular platform necessary for high local rasGAP activ-
ity. In addition, the Ras pathway is activated by Src and re-
quired for Src transformation of fibroblast cells (30, 31). Dok
may block Src transforming activity by interfering with Ras
GTP loading and mitogen-activated protein kinase activation.
Consistent with this model, we showed that Dok reduced Ras
GTP loading and did not affect cellular transformation trig-
gered by V12Ras, which is resistant to rasGAP activity. Fur-
thermore, in correlation with their inability to inhibit Src-
mediated transformation, Dok336, Dok277, and Dok-AA
mutants failed to associate with rasGAP in Src527F-trans-
formed cells. These observations suggest that one major func-
tion of Dok is to cluster rasGAP and thereby negatively regu-
late the Ras signal pathways. Increased PTK activity can result
in hyperphosphorylation of Dok. In turn, more negative regu-
lators such as rasGAP are recruited to the site of PTK activa-
tion to prevent Ras activation. Consistent with this model, it
was demonstrated that Dok inhibits Ras activity in 293 cells
(32). However, this model may not be universal, because Dok
could inhibit rather than enhance rasGAP activity in some cells
(33). One potential target of Dok is the mitogen-activated pro-
tein kinase pathway. We have shown recently that mitogen-
activated protein kinase activity is up-regulated in B lympho-
cytes from Dok2/2 mice (34). In addition, Dok is required to
mediate the inhibitory effect of FcgRIIB on Erk activation (35).
Furthermore, recent evidence has indicated that the Dok ho-
mologues Dok-R and Dok-L inhibit mitogen-activated protein
kinase activation induced by the epidermal growth factor re-
ceptor and v-Abl (17, 36).
Our results have indicated that there are at least two inde-
pendent functional domains in Dok, the carboxyl-terminal tail
FIG. 6. Dok binds rasGAP and interacts with the Ras signaling
pathway. A, Dok does not inhibit V12-K-Ras-induced transformation.
Focus-forming abilities of NIH3T3 cells expressing V12-K-Ras alone or
with Dok were compared. B, mutant Dok proteins are impaired in their
abilities to bind endogenous rasGAP. Lysates from cells that coex-
pressed Src527F and various HA-tagged Dok constructs were immuno-
precipitated with anti-HA antibodies and Western blotted with anti-
rasGAP antibodies. Whole-cell lysates were also probed with anti-HA
monoclonal antibodies. C, Dok inhibits Ras GTP loading in Src-trans-
formed cells. Active Ras (GTP-bound) was affinity-precipitated with
Raf-1 RBD agarose conjugate from NIH3T3 cell lysates that expressed
Src527 alone or with Dok and Western blotted using anti-Ras mono-
clonal antibodies. Ctr, control.
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and the amino-terminal PH and PTB domains. We have shown
that the carboxyl-terminal tail of Dok is necessary for Dok in
vivo activity. Dok relies on its carboxyl-terminal tail to recruit
Src homology 2-containing molecules such rasGAP and Nck (5,
12). Deletion of residues 278–481, which encompass the cluster
of potential tyrosine phosphorylation sites, was found to impair
the inhibitory ability of Dok. Deletional analysis has located a
minimum region (residues 336–363) on Dok that is essential
for its function. Interestingly, the sequence DPIY361DEPE
within this region is conserved among the Dok family proteins.
Furthermore, Tyr361 is also the major docking site for Nck and
rasGAP (4, 13). A recent study has demonstrated that Tyr361
plays a central role in Dok-mediated cell migration on insulin
stimulation (13). It is therefore possible that Tyr361 is impor-
tant for the inhibitory activity of Dok.
How does the amino-terminal domain of Dok modulate Dok
activities? The PTB and PH domains of Dok-R were shown to
be necessary for Dok-R phosphorylation by the epidermal
growth factor receptor (36). Therefore, the amino-terminal PH
and PTB domains may be important for efficient phosphoryla-
tion by protein-tyrosine kinases. In addition, phosphorylated
Dok-AA proteins had significantly decreased binding with en-
dogenous rasGAP, suggesting that an intact PTB domain may
be required to phosphorylate the rasGAP binding sites on Dok
or to recruit Dok to where rasGAP is localized.
Importantly, the amino-terminal region of Dok may be
needed for oligomerization of Dok and may recruit other sig-
naling proteins. Our data on the Dok PTB domain and Tyr146
support this model. We have shown that the Dok PTB domain
is capable of binding to phosphotyrosine-containing sequences.
Such binding is required for Dok function, because the Dok
PTB domain mutant that failed to bind phosphopeptides also
lost its ability to inhibit Src-mediated transformation. Further-
more, we have demonstrated that the PTB domain also medi-
ates Dok oligomerization by binding to the phosphorylated
Tyr146 site (located between the PH and PTB domains). The
Dok homotypic interaction may cluster Dok molecules at sites
of PTK activation. Consistent with the importance of oligomer-
ization, the Y146F mutation significantly decreased Dok inhib-
itory activity. Alternatively, the Dok PTB domain may bind
negative regulators such as phosphatase SHIP1 (23). There-
fore, the Dok amino-terminal domain may not only facilitate
tyrosine phosphorylation of Dok but also cluster Dok and its
associated proteins at the location for negative signaling.
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